It will contain modern technology and allow for a notable capacity increase, such as 2000L scale bioreactors and additional fill-finish capabilities.
According to Vibalogics CEO Tom Hochuli, the facility will create 100 jobs initially, and 250 positions over the next four years.
The CDMO was recently selected by J&J’s Janssen Pharmaceutical Companies as one of its manufacturing partners for its investigational Covid-19 vaccine candidate. The European Commission had previously approved an advance purchase agreement in which Janssen would supply 200 million doses of the vaccine following approval or authorization from regulators.
The post Vibalogics backs Boston virotherapy facility appeared first on Pharmaceutical Commerce.